ArticleTrauma surgery & acute care open2026
Early (<24 hours) venous thromboembolism prophylaxis in traumatic brain injury: development of the EViTBI algorithm using a national cohort.
Article in Trauma surgery & acute care open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Improved venous thromboembolism (VTE) prophylaxis in traumatic brain injury (TBI) is 'In-EViTBI-abl'.Trauma surgery & acute care open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractBackground: Optimal timing of venous thromboembolism (VTE) prophylaxis after traumatic brain injury (TBI) remains uncertain because of competing concerns regarding thromboembolism prevention and hemorrhagic progression. National recommendations remain inconsistent, and prophylaxis is frequently delayed beyond 72 hours. Objective: To develop and internally validate the early VTE prophylaxis in TBI (EViTBI) algorithm for identifying a reproducible low-risk cohort potentially eligible for early (<24 hours) pharmacologic prophylaxis. Methods: A retrospective cohort study was performed using the American College of Surgeons Trauma Quality Improvement Program Participant Use File (2017 to 2021). Adults with isolated TBI and complete prophylaxis-timing data were included. Multivariable logistic regression generated adjusted ORs for mortality, deep vein thrombosis (DVT), and pulmonary embolism (PE). Adjusted ORs were converted to weighted log-odds (mortality×2; VTE outcomes×1 negative) and summed to create the EViTBI score. Expert-derived thresholds were compared with receiver operating characteristic (ROC) and Youden Index analyses. Discrimination was assessed using the c-statistic. Results: Among 58 418 patients, 7590 (12.9%) received early prophylaxis. EViTBI classified 44.5% as low risk, 29.9% as moderate risk, and 25.5% as high risk. Compared with high-risk patients, low-risk patients had lower mortality (OR 0.15; 95% CI 0.13 to 0.17), DVT (OR 0.19; 95% CI 0.16 to 0.23), and PE (OR 0.23; 95% CI 0.17 to 0.31). Multivariable model discrimination was strong (c=0.740.75). The composite EViTBI score demonstrated acceptable discrimination for mortality (AUC=0.68). ROC and Youden analyses supported the expert-derived thresholds. Conclusion: EViTBI identified nearly half of isolated TBI patients as a reproducible low-risk cohort in whom early prophylaxis was associated with lower mortality and VTE rates. Findings are associative and hypothesis-generating; prospective validation incorporating serial imaging and prophylaxis fidelity is required before clinical implementation. Level of evidence: Prognostic study, level III.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.